^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT327

    i
    Other names: BNT 327, BNT-327, BNT327, PM8002, PM 8002, PM-8002
    Company:
    BioNTech, Biotheus
    Drug class:
    PD-L1 inhibitor, VEGF-A inhibitor
    Related drugs:
    8d
    PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (ChiCTR2400091077)
    P3, N=404, Recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital
    New P3 trial • Combination therapy
    |
    paclitaxel • topotecan • BNT327
    2ms
    PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=404, Not yet recruiting, Biotheus Inc.
    New P3 trial • Combination therapy
    |
    paclitaxel • topotecan • BNT327
    3ms
    A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC (clinicaltrials.gov)
    P1/2, N=140, Not yet recruiting, Biotheus Inc.
    New P1/2 trial • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • BNT327
    3ms
    BNT327-01: Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=110, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    BNT327
    3ms
    BNT327-02: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=60, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    BNT327
    3ms
    A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2/3, N=374, Active, not recruiting, Biotheus Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • IO biomarker • Metastases
    |
    carboplatin • pemetrexed • BNT327
    4ms
    PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=360, Recruiting, Biotheus Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    albumin-bound paclitaxel • BNT327
    4ms
    Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, BioNTech SE | Trial completion date: Apr 2026 --> Aug 2026
    Trial completion date • Combination therapy
    |
    BNT327
    4ms
    BNT327-02: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, BioNTech SE | Trial completion date: Apr 2026 --> Jan 2027
    Trial completion date • Combination therapy
    |
    BNT327
    5ms
    First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=842, Recruiting, DualityBio Inc. | N=607 --> 842
    Enrollment change • Metastases
    |
    Keytruda (pembrolizumab) • BNT327
    5ms
    Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, BioNTech SE
    New P2 trial • Combination therapy
    |
    BNT327
    5ms
    Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, BioNTech SE
    New P2 trial • Combination therapy
    |
    BNT327
    6ms
    PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=360, Not yet recruiting, Biotheus Inc.
    New P3 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    albumin-bound paclitaxel • BNT327
    10ms
    A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC (clinicaltrials.gov)
    P2/3, N=445, Recruiting, Biotheus Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Tecentriq (atezolizumab) • etoposide IV • BNT327
    over1year
    A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2/3, N=374, Recruiting, Biotheus Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 expression • EGFR mutation
    |
    carboplatin • pemetrexed • BNT327
    over1year
    A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM (clinicaltrials.gov)
    P2, N=55, Recruiting, Biotheus Inc.
    New P2 trial • Combination therapy
    |
    cisplatin • carboplatin • pemetrexed • BNT327
    over1year
    A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Biotheus Inc.
    New P1/2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    albumin-bound paclitaxel • BNT327
    over1year
    PM8002 in the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=380, Recruiting, Biotheus Inc.
    New P1/2 trial • Metastases
    |
    BNT327
    over1year
    A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC (clinicaltrials.gov)
    P2, N=99, Recruiting, Biotheus Inc.
    New P2 trial • Combination therapy
    |
    paclitaxel • BNT327
    over1year
    A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN (clinicaltrials.gov)
    P2, N=60, Recruiting, Biotheus Inc.
    New P2 trial • Combination therapy
    |
    5-fluorouracil • irinotecan • leucovorin calcium • BNT327
    over1year
    PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=35, Recruiting, Biotheus Inc.
    New P2 trial • Combination therapy
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • BNT327
    over1year
    A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC (clinicaltrials.gov)
    P2/3, N=445, Not yet recruiting, Biotheus Inc.
    New P2/3 trial • Combination therapy
    |
    Tecentriq (atezolizumab) • etoposide IV • BNT327